TORONTO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, ...
TORONTO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, ...
— Clinical evidence continues to highlight TULSA’s ability to treat an unrivalled variety of patients with localized prostate cancer and/or BPH — “The various presentations made at AUA and other major ...
(MENAFN- GlobeNewsWire - Nasdaq) Milestone reflects accelerating adoption of innovative, non-surgical treatment options for uterine conditions TORONTO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Profound ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results